OncoMatch/Clinical Trials/NCT06656494
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Is NCT06656494 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including ICP-248 and Azacitidine for acute myelogenous leukemia.
Treatment: ICP-248 · Azacitidine — Evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ICP-248 in combination with azacitidine in patients with acute myelogenous leukemia and Myelodysplastic Syndromes.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Prior therapy
Cannot have received: azacitidine or BCL-2 inhibitor
Exception: no response or intolerance to post azacitidine or BCL-2i
R/R AML or R/R MDS with no response or intolerance to post azacitidine or BCL-2i
Lab requirements
Kidney function
creatinine clearance ≥ 30 mL/min; determined via urine collection for 24-hour creatinine clearance or by the Cockcroft-Gault formula
Liver function
adequate liver function
adequate renal function as demonstrated by a creatinine clearance ≥ 30 mL/min; adequate liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- NYU Langone Health · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify